Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
PT-141 (Bremelanotide)
In plain language
PT-141 (Vyleesi) is the -approved melanocortin agonist for hypoactive sexual desire disorder. Acts centrally via MC4R.
For researchers
PT-141 (Bremelanotide) is a synthetic 7-amino acid melanocortin agonist, an α-MSH analog with activity primarily on the MC4R receptor. Developed by Palatin Technologies. Under the trade name Vyleesi it was -approved in 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The mechanism is central — acts at the hypothalamic level (not peripherally like PDE-5 inhibitors of the Viagra type), stimulating sexual desire and arousal via the melanocortin system. Originally developed as a self-tanner (before the sexual effect was established). RECONNECT 1 and 2 clinical trials document statistically significant improvement in sexual function in women. Administered s.c. or intranasally; peak effect 1-3 hours. Storage: -20°C lyophilized.
Scientific literature
Other peptides
Information about PT-141 is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.